Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
Melanoma today is considered as a spectrum of melanocytic malignancies characterised by clinical and molecular features, including targetable mutations in several kinases such as BRAF or c-KIT. The successful development of therapies targeting these mutations has resulted in new specific treatment o...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041182/ https://www.ncbi.nlm.nih.gov/pubmed/26217117 http://dx.doi.org/10.1016/j.ejcsup.2013.07.011 |